Philogen announces its attendance at the Antibody Engineering & Therapeutics 2022.
Prof. Dario Neri, CEO and CSO of Philogen, is giving a lecture entitled “Small Molecule-drug Conjugates (SMDCs) and Antibody-drug Conjugates (ADCs): A Comparative Evaluation”
Please follow the link below for more information